PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Authors:

Abstract:

105 patients with relapsing-remitting multiple sclerosis aged 18 to 49 were examined. The degree of disability was assessed using the Expanded Disability Status Scale. Neuropsychological examination was performed to determine the level of personal and reactive anxiety on the Spielberger-Khanin scale and depression on the Beck scale. Magnetic resonance imaging of the brain was performed and brain atrophy indices were calculated, namely, the bicaudal and Sylvian sulcus indices. The ability of the studied clinical and paraclinical indicators to predict the progression of disability in multiple sclerosis was assessed using ROC analysis. Areas under the ROC curve had excellent prognostic characteristics for indices of atrophy, levels of anxiety and depression about significant neurological manifestations (EDSS≥3.5 points) and disability in patients with relapsing-remitting multiple sclerosis. According to the data of the multiple logistic regression analysis, it was established that the degree of subcortical atrophy according to the BCR index is a statistically significant independent factor affecting the appearance of significant neurological manifestations, according to the adjusted odds ratio, purified from the influence of other factors (OR=26.2; 95 % CI 3.5–198.3), the level of depression on the BDI scale (OR=97.2; 95 % CI (3.4–2744.0). A significant protective effect of disease-modifying therapy was confirmed (OR=0.006; 95 % CI 0.001–0.045).

Keywords:

multiple sclerosis atrophy disability prognosis course

References:

1. Pinchuk VA, Delva M.Yu., Hryn KV. Prohnozuvannia perebihu rozsiyanoho sklerozu na pidstavi klinichnykh osoblyvostey debiutu u patsiyentiv Poltavskoyi oblasti. Ukrainskyi zhurnal medytsyny, biolohiyi ta sportu. 2023;8(1):146–150. doi: 10.26693/jmbs08.01.146 [in Ukrainian]
2. Cohan SL, Benedict RH, Cree BA, DeLuca J, Hua LH, Chun J. The two sides of Siponimod: Evidence for brain and immune mechanisms in multiple sclerosis. CNS Drugs. 2022;36(7):703–19. doi:10.1007/s40263-022-00927-z
3. Kern S, Geiger M, Paucke M, Kästner A, Akgün K, Ziemssen T. Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. Journal of Molecular Medicine. 2019;97(11):1547–55. doi:10.1007/s00109-019- 01821-w
4. Masuccio FG, Gamberini G, Calabrese M, Solaro C. Imaging and depression in multiple sclerosis: A historical perspective. Neurological Sciences. 2021;42(3):835–45. doi:10.1007/s10072-020-04951-z
5. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis. JAMA. 2021;325(8):765. doi:10.1001/jama.2020.26858
6. Ohlmeier C, Gothe H, Haas J, Osowski U, Weinhold C, Blauwitz S, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real World evidence based on German claims data. PLOS ONE. 2020;15(5). doi: 10.1371/journal.pone.0231846
7. Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. International Review of Psychiatry. 2017;29(5):463–72. doi:10.1080/09540261.2017.1322555
8. Rekik A, Aissi M, Rekik I, Mhiri M, Frih MA. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates. Brain and Behavior. 2022;12(5). doi:10.1002/brb3.2573
9. Solaro C, Gamberini G, Masuccio FG. Depression in multiple sclerosis: Epidemiology, Aetiology, diagnosis and treatment. CNS Drugs. 2018;32(2):117– 33. doi:10.1007/s40263-018-0489-5
10. Sorensen PS, Sellebjerg F, Hartung H-P, Montalban X, Comi G, Tintoré M. The apparently milder course of multiple sclerosis: Changes in the diagnostic criteria, therapy and natural history. Brain. 2020;143(9):2637–52. doi:10.1093/brain/awaa145
11. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the atlas of MS, Third edition. Multiple Sclerosis Journal. 2020;26(14):1816–21. doi:10.1177/1352458520970841

Publication:

«World of Medicine and Biology» Vol. 19 No. 84 (2023) , с. 147-152
УДК 616.8-004-036.86/.87-07-037

DOI:

https://doi.org/10.26724/2079-8334-2023-2-84-147-152